These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: In vitro activity of grepafloxacin (OPC-17116) against anaerobic bacteria.
    Author: Wexler HM, Molitoris E, Finegold SM.
    Journal: Diagn Microbiol Infect Dis; 1994 Jun; 19(2):129-33. PubMed ID: 7805357.
    Abstract:
    In vitro activity of the quinolone grepafloxacin (OPC-17116) was compared with that of ciprofloxacin, fleroxacin, clindamycin, imipenem, and metronidazole by using the NCCLS-approved Brucella-base-laked blood agar dilution method and breakpoints, when available. Clindamycin, metronidazole, and imipenem inhibited > or = 98% of Bacteroides fragilis at the breakpoint; grepafloxacin, ciprofloxacin, and fleroxacin inhibited 83%, 6%, and 0, respectively, at 2 micrograms/ml. Grepafloxacin inhibited 39% of other B. fragilis group species isolated (80) at breakpoint (< or = 2 micrograms/ml) compared with 100% for metronidazole and imipenem, 83% for clindamycin, 6% for ciprofloxacin, and 1% for fleroxacin. Grepafloxacin demonstrated substantially better activity against B. fragilis than did ciprofloxacin or fleroxacin; overall activity against anaerobes was marginally better than that of ciprofloxacin or fleroxacin.
    [Abstract] [Full Text] [Related] [New Search]